We examined the microRNA (miRNA) expression profile of 40 prostatectomy specimens from stage T2a/b, early relapse and nonrelapse cancer patients, to better understand the relationship between miRNA dysregulation and prostate oncogenesis. Paired analysis was carried out with microdissected, malignant and non-involved areas of each specimen, using high-throughput liquidphase hybridization (mirMASA) reactions and 114 miRNA probes. Five miRNAs (miR-23b, -100, -145, -221 and -222) were significantly downregulated in malignant tissues, according to significance analysis of microarrays and paired t-test with Bonferroni correction. Lowered expression of miR-23b, -145, -221 and -222 in malignant tissues was validated by quantitative reverse transcription (qRT)-PCR analyses. Ectopic expression of these miRNAs significantly reduced LNCaP cancer cell growth, suggesting growth modulatory roles for these miRNAs. Patient subset analysis showed that those with post-surgery elevation of prostatespecific antigen (chemical relapse) displayed a distinct expression profile of 16 miRNAs, as compared with patients with nonrelapse disease. A trend of increased expression (440%) of miR-135b and miR-194 was observed by qRT-PCR confirmatory analysis of 11 patients from each clinical subset. These findings indicate that an altered miRNA expression signature accompanied the prostate oncogenic process. Additional, aberrant miRNA expression features may reflect a tendency for early disease relapse. Growth inhibition through the reconstitution of miRNAs is potentially applicable for experimental therapy of prostate cancer, pending molecular validation of targeted genes.
Introduction
MicroRNAs (miRNA) were first discovered as small temporal RNAs that regulate critical events in Caenorhabditis elegans development. 1 Endogenously occurring miRNAs were subsequently identified in mammalian cells, and exhibited similar, post-transcriptional gene regulatory activities. 2, 3 Up to 33% of all gene coding mRNAs are negatively regulated by miRNAs in mammalian cells. 4, 5 It is now evident that the limited repertoire of miRNAs (over 500 identified so far) can profoundly modulate the steady-state function of diverse physiologic events. 4, 6 Approximately half of miRNA genes (miRs) are encoded in genomic regions prone to cancer-associated alterations, including fragile sites (FRA), minimal regions of loss of heterozygosity, minimal regions of amplification (minimal amplicons) or common breakpoint regions. 7 Other miRs are located inside or near homeobox (HOX) genes and are hence susceptible to collateral deregulation that was evident in various solid and hematopoietic cancers. Epigenetic defects may also affect mature miRNA activity. 8 As gene targets for miRNAs are being defined, there is increasing evidence that altered expression of regulatory miRNAs can directly or indirectly impact oncogenic, tumor suppressor, or angiogenic pathways. [8] [9] [10] [11] [12] [13] Prostate cancer is the most common cancer in man and the second leading cause of death in the United States. 14, 15 It is estimated that 186 000 new cases will be diagnosed in 2008, with 28 000 expected deaths. Patients who present with localized disease may be cured through radical prostatectomy or irradiation, albeit with considerable negative impact on health-related quality of life. A subset of these patients, however, is prone to disease relapse, and yet histologically indistinguishable from others with a more benign clinical course. Both preoperative prostatespecific antigen (PSA) velocity and PSA doubling time have been used as predictors of biochemical progression, clinical progression and death from prostate cancer. 15, 16 However, a significant number of potentially aggressive prostate cancers may go undetected in men with low/ normal PSA values, indicating the need to develop biomarkers that can potentially supplement or even replace PSA for the diagnosis and prognosis of prostate cancer. 16 Recent studies by Lu, Volinia and co-workers showed that various human epithelial cancers, including prostate cancer, displayed miRNA signatures that differed from their normal counterparts. 12, 17, 18 The miRNA expression profile of human breast cancer 19 and hepatocellular carcinoma 20 has been correlated with prognostic, biopathologic features, although it is uncertain whether clinically distinct cancer subsets can be defined by these unique miRNA phenotypes. We recently conducted paired miRNA profiling analysis of normal and malignant tissues of prostatectomy specimens from 40 patients diagnosed with stage T2 prostate cancer to characterize the miRNA expression profile in early disease. Differential miRNA expression was explored in patients with early chemical relapse (o2 years post-prostatectomy) and those without clinical relapse for a period of more than 10 years. Our findings suggest that altered miRNA expression likely accompanied the prostate oncogenic process, with the early relapse subset earmarked by additional aberrant miRNA features prior to clinical relapse.
Materials and methods

Cell lines
LNCaP clone FGC (prostate carcinoma) was obtained from the American Type Culture Collection (Manassas, VA). This cell line was cultured in RPMI 1640 medium with 10% fetal bovine serum (Atlanta Biological, Atlanta, GA).
Patient population and samples
In total, 40 formalin-fixed paraffin-embedded (FFPE) prostatectomy specimens were analyzed from clinically diagnosed prostate cancer patients with well-documented clinical follow-ups. Twenty specimens were from patients with early chemical relapse (o2 years post-prostatectomy), defined as having two consecutively elevated PSA values at follow-up visit. Twenty additional samples were derived from patients without chemical relapse within a period of 10 years post-prostatectomy. All of 40 patients were pathology stage T2a/b at the time of surgical resection. The chemical relapse and non-relapse subsets were matched for age at diagnosis (61.8 ± 6.1 years for non-relapsed vs 59.4±8.7 years for early-relapse subset) and Gleason score (5.7±1.0 vs 6.2±0.6, respectively). PSA level for the relapsed group (11.2 ± 7.9) was significantly higher (Po0.008) than that of non-relapsed patients (6.0±2.7) at the time of diagnosis. Stage T2b patients (tumor involving both lobes) were over-represented in the chemical relapse group (15 of 20) as compared with non-relapse patients (6 of 20; P ¼ 0.01, Fisher's exact test). For each specimen, areas of malignancy were microdissected from uninvolved areas, and comprised X80% tumor cells according to histopathological features. Microdissected, malignant areas encompassed involved individual glands and some neighboring stroma. Research protocols involving human subjects were approved by the Institutional Review Board at Baylor University Medical Center and the Presbyterian Hospital.
RNA extraction
Total RNA was extracted in parallel from each malignant and non-malignant specimen pair by methods known to preserve the integrity of small RNAs (FFPE PureLink RNA Isolation kit; Invitrogen, Carlsbad, CA). Approximately 400 mm (at 10-mm slices) of FFPE tissue was harvested for RNA extraction, with an average yield of 10-20 mg of total RNA per microdissected specimen. All RNA was quantified spectrophotometrically according to 260/280 ratios (NanoDrop ND-1000; Thermo Fisher Scientific, Inc., Wilmington, DE). Small RNA integrity was verified by electrophoresis using the Bio-Rad Experion RNA StdSens chip (Bio-Rad, Hercules, CA). Total RNA was extracted from frozen LNCaP cell pellets using the PureLink, miRNA extraction kit (Invitrogen).
mirMASA analysis Multiplex analysis of miRNA expression was determined by the mirMASA technique (Genaco Biomedical, Huntsville, AL), based on liquid-phase hybridization reactions with oligonucleotide probe-conjugated fluorescent beads. miRNA binding was quantified with Fluorokine MultiAnalyte Profiling (xMAP) flow cytometry of the Luminex platform. 21 Each set of color-coded microsphere (bead) is covalently coupled with a capture oligonucleotide and a biotin-labeled detection oligonucleotide. The 12-nt capture oligonucleotide recognizes the 3 0 end portion of the miRNA, whereas a short (8-10 nt), biotin-labeled detection oligonucleotide hybridizes to the 5 0 end of the same miRNA. Both capture and detection oligos are spiked with locked nucleic acid nucleotides to increase specificity and sensitivity, 22 making it possible to detect even a single base difference among miRNAs.
The miRNA detection panel comprises 114 miRNA probe sets directed at commonly interrogated human miRNAs (http://microrna.sanger.ac.uk/sequences/) and previously validated for the lack of cross-reactivity with other miRNAs. 23 Hybridization was carried out with preoptimized panels of 10-12 probes per panel. Each panel was incubated at 45 1C for 1 h in the dark with 1 mg of total RNA (from total harvested RNA of 10 mg from each microdissected sample), followed by streptavidinconjugated phycoerythrin (45 1C, 10 min) with washings in between. A probe set for 5S RNA is incorporated into each panel as an internal loading control. Validation studies using equimolar concentrations of precursor and mature miR-15b and miR-17-5p showed that this approach preferentially detected mature miRNA in tissue-extracted RNAs, whereas binding of the corresponding precursors was negligible (data not shown). One apparent explanation is the formation of a doublestranded structure in the precursors that prevents their interaction with the capture and detection oligonucleotides.
Analysis of miRNA expression in malignant and nonmalignant tissues from the same patient was carried out concurrently. miRNA binding was quantified as a function of mean fluorescence intensity (MFI) following incubation with streptavidin-conjugated phycoerythrin, 24 based on a minimum of 100 events per probe set. From a statistical point of view, this approach represents 100 data points per target. Mean binding activity for each miRNA was normalized to parallel reactions of 5S RNA hybridization to control intersample technical variations. Within the study population, 5S expression in tumor tissues (MFI of 8526±678 (mean±s.d.), n ¼ 40) did not differ significantly from their normal counterparts (8400 ± 763, n ¼ 40; P ¼ 0.53, Student's two-sided t-test). Further, 5S RNA expression from each patient's nonmalignant and malignant tissue did not differ significantly from one another, based on Student's two-sided paired t-test (P ¼ 0.38, n ¼ 40). A negative bead control was performed for each reaction set. A hybridization reaction is deemed positive if the MFI value is X2-fold higher than negative control. The dynamic range of this assay is 42 logs with a coefficient of variation of 1.7%, and a minimal sensitivity of 0.1 fm for synthetic miRNAs.
Populational analysis
For normalization of data for population analysis, log transformation was carried out with an offset to accommodate zeros by the formula [x 0 ¼ log 2 (x þ 1)], where x 0 represents the adjusted value and x, the observed MFI after background subtraction. Differential expression for each individual miRNA is represented as a T/N ratio by comparing binding activity by tumor (T) vs normal (N) tissue-extracted miRNAs from the same patient, following normalization to 5S RNA expression (Supplementary Table 1 ). Normalized T/N ratios were imported into Gene Spring 7.3.1 (Agilent Technologies, Forest City, CA) for hierarchical analysis, and sorted by Gene Spring standard linkage and Euclidian distance cluster analysis (Supplementary Figure 1) . Genes that were differentially expressed between tumor and normal samples were identified by two-class paired significance analysis of microarrays (SAM) 24 with default parameters. Analysis was performed using the R statistical environment.
Real-time quantitative reverse transcription (qRT)-PCR
Synthetic miRNAs were generated (IDT DNA Synthesis Labs, Coralville, IA) according to published sequences (Sanger miRNA database). In total, 100 ng of harvested, patient total RNA was used as a starting material for realtime quantitative reverse transcription PCR (qRT-PCR) reactions, using pre-qualified amplification kits for cDNA generation (TaqMan hsa-miR-20a, -23b, -100, -141, -143, -145, -221 and -222 amplification kits; Applied Biosystems, Foster City, CA) and subsequent real-time qRT-PCR reactions (40 cycles) according to the manufacturer's protocol. Primer probe sets were preselected to exclude precursor miRNA amplification (Applied Biosystems). Defined concentrations of synthetic miRNA (1 ng-1 fg) were used as template and analyzed in parallel with patient specimens to generate a standard curve for quantification of unknown miRNA levels. All reactions are normalized by template input (total RNA), according to the manufacturer's protocol.
Differential expression analysis of chemical relapse and non-relapse subsets mirMASA-based T/N findings for each miRNA were also used for hierarchical segregation of relapse and nonrelapse patient subsets, as described above. Sixteen miRs were identified, using the support vector machines (SVMs) algorithm and the (nÀ1) cross validation, as displaying distinct expression profiles in relapse and nonrelapse patient subsets (Supplementary Table 2) .
qRT-PCR analysis was performed on a subset of 13 miRNAs with commercially available, prequalified analytic kits (miR-16, -23a, -34c, -96, -122a, -129, -135b, -140, -154, -194, -218, -298 and -342; TaqMan MicroRNA Assay; Applied Biosystems), based on the techniques described above. miRNAs that exhibited expression levels below the simultaneously generated standard curve in four or more patients in either clinical subset (miR-23a, -34c, -96, -122a, -129, -154 and -298) were not analyzed further. Relative expression of each miRNA between the clinical subsets was determined by comparison of their T/ N ratios (mean T/N relapse /mean T/N non-relapse ).
Cell viability assays
To determine the growth regulatory effect of miRNA expression, target cells (4.5 Â 10 4 ) suspended in growth medium were seeded into 24-well plates, and transfected with predefined, synthetic miRNA (50 nM, miRIDIANS; Dharmacon, Chicago, IL) according to the manufacturer's protocol (siPORT Transfection Reagent; Ambion, Austin, TX). Transfection efficiency was determined by reporter gene expression (gWiz-GFP plasmid; Aldevron, Fargo, ND) in a parallel transfection procedure. Cell viability was determined in triplicate by a standard Trypan blue exclusion assay. 25 Enumeration of total and viable cell numbers in a hemacytometer chamber was performed by two independent observers by light microscopy.
Results
Human prostate cancer signature by array analysis
Validation studies performed by us and others demonstrated that small RNAs were preserved after the FFPE process. 26, 27 Detected levels of individual miRNAs were decreased in FFPE cells, but proportionate to, and strongly correlated with the corresponding expression level in cryopreserved specimens (r 2 ¼ 0.93, P ¼ 0.0001).
Our current analyses employed archived FFPE specimens derived from surgically resected prostatectomy procedures performed in the course of treatment for prostate cancer. Individual patient specimens were microdissected into histopathologically defined malignant and nonmalignant subsets. This approach allowed for an internally controlled comparison of the miRNA expression profile of malignant and non-malignant tissues from each patient. Total RNA harvested from each subset was analyzed in parallel by the mirMASA assay, a liquidphase multiplex analytical approach utilizing hybridization probes for 114 miRNAs. 17, 21, 23 Pre-validation studies using synthetic miRNAs showed that s.d.s for replica determinations were 2-9% of the mean value. Readouts were normalized to the hybridization reaction of 5S RNA, the expression of which in tumor and normal tissues of individual patients did not differ significantly from one another (P ¼ 0.38; Student's two-sided paired t-test) in our study population. Paired differential analysis was carried out to arrive at a tumor/normal (T/N) expression ratio for individual miRNAs (Supplementary Table 1 ). The mean populational T/N expression ratio is analyzed statistically against the null hypothesis of a T/N ratio of 1.
More than 95% of the 114 probed miRNAs (except miR-207, -211 and -322) displayed a positive hybridization signal in our 40 paired prostate tissues examined. The unamplified levels of the majority of miRNAs were relatively unchanged in malignant tissues as compared with their normal counterpart (Supplementary Figure 1) . However, nine miRNAs (miR-23b, -24, -100, -125b, -143, -145, -205, -221 and -222) were significantly reduced in malignant prostate cancers, according to hierarchical cluster analysis and the SAM algorithm used to reveal differentially expressed miRNAs along with an estimate of the false discovery rate (Figure 1 ). In particular, the decreased expression of a subset of five miRNAs (miR23b, -100, -145, -221 and -222) was validated by the more stringent, paired t-test with Bonferroni correction (Po0.05). The T/N values for these reduced miRs in all 40 patients are shown in Figure 2 . Mean reduced expression ranged from approximately 56% (miR-222) to 24% (miR-100; Table 1 ) in malignant tissues.
SAM analysis also identified seven miRNAs that were upregulated in malignant prostate cells (miR-20a, -25, -122a, -129, -141, -302 and let-7a) (Figure 1) . None of the seven, however, attained significance when analyzed by t-test with Bonferroni correction (Table 1 ). These findings indicate that reduced expression of miR-23b, -100, -145, -221 and -222 likely accompanied the prostate malignant process.
Validation of miRNA expression by qRT-PCR
To validate the downregulation of miR-23b, -100, -145, -221 and -222 in malignant prostate cancer cells, real-time qRT-PCR analysis was carried out with miRNA-specific primer/probe sets under preoptimized conditions. Primer/ probe sets were preselected to exclude precursor miRNA amplification. Twelve patient specimens, six from each clinical subset, were selected for their representative miRNA expression profile as displaying decreased levels of miR-23b, -100, -145, -221 and -222 by mirMASA. The overall T/N ratios as determined by RT-PCR strongly correlated with mirMASA findings when all six miRNAs were analyzed collectively (P ¼ 0.002, binomial test). Significant correlations were also demonstrated for individual miRNAs miR-23b, -143, -145, -221 and -222, based on the small numbers of samples tested (mean T/N ratio of 0.84, 0.76, 0.56, 0.85 and 0.62, respectively; Table 2), with miR-100 (T/N ratio of 0.89) approaching statistical significance (Po0.06). qRT-PCR analysis confirmed downregulated miR-100 expression in four of eight patients who exhibited a reduced expression by X20% by mirMASA (Table 2 ). This discrepancy may be partly attributed to the higher sensitivity of the mirMASA assay in discriminating moderate reductions of miRNA expression. 28 Real-time qRT-PCR also confirmed the upregulated expression of miR-20a and -141 in 7 of 12, and 10 of 12 malignant prostate tissues tested, and Differential miRNA expression in prostate cancer AW Tong et al Figure 2 Scatterplot of patient T/N ratios. Scatterplot of T/N expression ratios for individual patients is shown for miR-23b, -100, -145, -221 and -222, the expression of which was found to be significantly decreased, based on population analysis by SAM and paired t-test with Bonferroni correction. Expression readouts were normalized to the hybridization reaction of 5S RNA, then subjected to paired differential analysis to arrive at a tumor/normal (T/N) expression ratio for individual miRNAs. Line represents median expression level for each miRNA. b Concordance of T/N ratios by mirMASA vs qRT-PCR findings was determined by the formula P ¼ 1/2 n , where n is the number of samples that demonstrate a similar direction of change (up-or downregulation) by both assays. The combined P-value for all miRs ¼ 0.002. d log 2 T/N ratios are shown in parentheses.
corresponded to an mean increased T/N ratio of 6.69 and 2.58, respectively. As an internal reference correlative control, the expression analysis of let-7f miRNA showed no change between tumor and normal tissue by mirMA-SA (T/N ratio of 1.0 ± 0.18) or by qRT-PCR (1.1 ± 0.30).
Growth regulatory effect of miRNA reconstitution
To explore the pathophysiologic relevance of the prostate cancer miRNA signature, reconstitutive studies were carried out with miRNAs that demonstrated reduced expression in malignant tissues by both mirMASA and qRT-PCR. The prostate cancer line LNCaP displayed a similar phenotype of reduced expression of miR-23b, -145, -221 and -222, and increased miR-141 (Table 3) . Lipofection was carried out with oligonucleotide constructs corresponding to the mature sequence of each miRNA. Reconstitution of downregulated miRNAs resulted in diminished LNCaP cancer cell growth, a phenomenon that was both time (plateau at 48 h) and dose (growth reductions of 15% at 12.5 nM, 24% at 25 nM and 36% at 50 nM for miR-222) dependent. An optimal dose of 50 nM was selected for subsequent studies as the treatment dose of 100 nM did not further promote growth inhibitory outcome. Ectopic expression of miR-23b, -145 and -222 significantly inhibited LNCaP growth by 42, 40 and 36%, respectively at 24 h post-transfection (Figure 3 ), as compared with the untreated culture (Pp0.002, Student's two-tailed t-test, n ¼ 3 per miRNA). This level of growth inhibition compared favorably with a transfection efficiency of 40.8 ± 5.4%, as determined by reporter gene (gWiz-GFP plasmid) analysis. Reconstitution with miR-221 was not carried out in view of the expected overlapping targeting activity with miR-222. [29] [30] [31] In contrast, reconstitution with miR-141, which was upregulated in LNCaP and in 75% of patient samples, did not significantly alter the growth of LNCaP cells (o4% growth inhibition, P40.05 as compared with mock-transfected cells; Figure 3) . Similarly, mock transfection, or treatment with cel-miR-67 (C. elegans miRNA with minimal sequence identity with human miRNAs) did not significantly impact LNCaP growth.
Interestingly, combined treatment with equimolar (16.6 nM each) concentrations of miR-23b, -145 and -222 did not generate a synergistic inhibitory response (44% growth inhibition; Figure 3 ). The effective dose to achieve 50% growth inhibition (ED 50 ) for miR-23b, miR-145 and miR-222 was 84.5, 52.8 and 75 nM, respectively, according to dose-response studies, as compared with the molar equivalent of 55.9 nM in the combined treatment of all three miRNAs. The capacity to inhibit prostate cancer cell growth through transient expression is suggestive of a growth regulatory role for the downregulated miRNAs in prostate oncogenesis. This reconstitutive approach may serve as a viable experimental therapeutic approach for human prostate cancer.
miRNA expression in early relapse prostate cancer To consider whether clinically aggressive prostate cancers display a distinguishable, predictive miRNA phenotype, differential analysis was carried out to examine the Table 2) .
Follow-up qRT-PCR analysis was performed on the same, residual patient biopsies that yielded adequate amounts of RNA (n ¼ 11 for each clinical subset). We identified a concordance of upregulated expression of miR-16, miR-135b, miR-194 and miR-218, and downregulated miR-140. T/N ratios that were determined by mirMASA and qRT-PCR did not differ significantly from one another for these miRNAs (P40.05, Student's twotailed paired t-test). A X40% difference in expression between the relapse (R) and non-relapse (NR) subsets was observed for miR-135b (R/NR ratio of 1.6) and miR-194 (1.4), although this trend of differential expression did not attain statistical significance for the limited number of patients analyzed (P40.05, Mann-Whitney test). Our preliminary findings suggest that prostate cancers with early relapse tendencies may display a distinguishing miRNA signature. However, analysis with a more robust sampling size for each clinical subset is clearly needed, to address the likelihood of phenotypic heterogeneity within each clinical subset.
Discussion
The capacity of miRNAs in specifying cellular phenotype of eukaryotic cells through polyspecific, post-transcriptional modulation has been demonstrated in multiple experimental models. 4, 12, 28, 29 Several lines of evidence support a contributory role by aberrant miRNA activity to the human malignant phenotype. Altered miRNA expression is highly prevalent in human cancers, and parallels chromosomal defects in the corresponding miRNA coding regions and/or epigenetic defects in hematopoietic malignancies and solid cancers.
7-10 miR-NA expression profiles that correlate with unique pathophysiological features have been identified in multiple cancer cell types, including breast and colorectal cancers. 19, 20, 30 Further, an increasing number of oncogene or tumor suppressor genes have now been identified as targets of aberrantly expressed miRNAs, including let-7, miR-15a/16, miR-17-92, miR-21, miR-106, miR-155 and miR-143/145. 4, 8, 12, 26 In view of the natural function of miRNAs as post-transcriptional regulators of cell growth and differentiation, and the markedly lower complexity in the miRNA paradigm (an expression database of over 500 currently known miRNAs, as compared with over 30 000 readouts for coding mRNAs), the elucidation of differentially expressed miRNAs present an attractive venue toward the development of cancer prognosticators and/or experimental treatment.
Currently, data regarding the miRNA expression profile in prostate cancer are limited. We have utilized a paired analytical approach to determine the differential miRNA expression pattern for individual patients with early-stage prostate cancer. Our study utilized a beadbased liquid-phase hybridization approach similar to that described by Lu et al., 17 who first utilized this highthroughput platform to successfully classify human cancers and defined the human lung cancer phenotype. Compared with the solid-phase array-based analyses, liquid-phase hybridization may be more sensitive in identifying modest changes in miRNA expression, 17, 23 despite the labor intensiveness of this approach. The requirement of sequence-specific binding to the capture and detection probe is expected to improve discrimination of closely related miRNA, 23, 26 although this premise needs to be further validated. Although differential expression of coding mRNA between normal and malignant tissues may differ by orders of magnitude, relatively modest differences of 1-to 2-fold, or less, were commonly seen for individual miRNAs. 5, 31, 32 This consideration, together with unique technical features in our analysis, may explain the comparatively modest differential T/N expression ratios observed in our study.
Our analysis did not utilize a preamplification step of patient small RNAs, to maintain linearity in the quantitative measurements of miRNA expression levels. Further, we elected to concurrently analyze microdissected malignant and non-malignant tissues from the same patient, with an aim to achieve a more precise correlation of differential miRNA expression and the malignant transformation process. An unavoidable inclusion of normal, neighboring stroma in the microdissected, involved malignant tissues, or incorporation of hyperplastic/premalignant areas in the non-malignant compartment may also reduce the calculated T/N ratio. T/N ratios were calculated following normalization to parallel reactions of 5S RNA hybridization, to control for intersample technical variations. A wide range of transformed and tumor cell types have been found to have elevated RNA polymerase III activity, which in turn may result in the increased expression of essential, short untranslated transcripts such as 5S rRNAs. 33 However, 5S RNA expression did not differ significantly between malignant and normal tissues in our study population.
This paired analytical approach has allowed the identification of five miRNAs (miR-23b, -100, -145, -221 and -222) that were deemed to be significantly downregulated by the statistical criteria of SAM and paired t-test with Bonferroni correction. The stringency of these findings was supported by real-time RT-PCR analysis for miR-23b, -143, -145, -221 and -222, with the use of primer/probe sets that were preselected to exclude precursor miRNA amplification. We also observed a decreased expression of miR-100 that approached statistical significance in the same correlative analysis. The collateral downregulation of miR-221 with miR-222, and to a lesser extent, miR-145 with miR-143, serves to indirectly support the validity of our findings.
Our observations were supported by several recently published reports on prostate cancer miRNA phenotypes that were based on a limited number of samples. Decreased expression of mir-23b, -143, -145, -222, as well as miR-100, has been designated as part of the 46 miRNAs in a prostate cancer signature found in two primary needle core biopsies and the fine needle aspirate of a metastatic lesion. 34 The reduction of miR-145, miR-143, miR-221 and miR-222 that we observed in stage T2a/b prostate cancer specimens was also noted among the 22 miRNAs that were decreased in five untreated and four hormone-refractory prostate carcinomas, according to Porkka et al.'s 35 study that utilized an array-based hybridization analysis. In a comparative analysis of prostate cancer lines, miR-221 and miR-222 were overexpressed in the more aggressively growing PC3 line as compared with slower growing LNCaP and 22Rv1 cells. 36 Our findings were also consistent with the recent report by Ozen et al., 37 who showed that miR-145 was one of the most frequently downregulated miRNAs (with a median decrease of approximately 60%) in 16 prostatectomy samples from patients with or without chemical relapse. There is also some degree of congruence with the recently reported results of array-based miRNA hybridization of prostate cancer tissue from 60 patients as compared with 16 samples of non-tumor-bearing prostate, in which miR-145, miR-205 and miR-221 were downregulated and miR-25 was overexpressed. 38 It is of interest to note that the five miRNAs identified in our study have been shown to be dysregulated in other human cancers. miR-143 and miR-145 are localized to sites of frequent chromosomal instability, 39 and best known for their consistently reduced expression levels at the adenomatous and cancer stages of colorectal cancer. 40, 41 Reduced miR-145 expression has been documented in hepatocellular carcinoma, lung cancer and in breast cancer, where decreased miR-145 and miR-143 correlated with a high proliferative index. 19 miR-221 and miR-222 are encoded in tandem on chromosome X. 36 Interestingly, upregulated miR-221 and miR-222 were associated with oncogenesis of cancers of the neural crest, including glioblastoma multiforme 42 and thyroid papillary carcinoma. 43 miR-23 has been implicated in the pathway specification for neural differentiation 44 as a prodifferentiative regulatory miRNA. 45 Hence, its downregulation may favor the tumor transformational process.
These parallel findings suggest that prostate oncogenesis is accompanied by altered expression of regulatory miRNAs. Clearly, the pathophysiologic role of the relevant players requires further molecular validation. Recently, miR-20a, a member of the miR-17-92 cluster, was found to modulate the translation of the E2F2 and E2F3 mRNAs, and exhibited antiapoptotic activity in the PC3 prostate cancer cell line. 46 We observed an increased miR-20a expression by various degrees in the majority of patients, which lends credence to the speculation that antiapoptotic activity from dysregulated E2F family member expression may potentially contribute to prostate cancer cell survival. The loss of function of miR-146a, which targets the kinase ROCK1, 47 or miR-125b, which limits the expression of the translational regulator EIF4EBP1, 37 has been implicated in prostate malignant transformation. Neither of these miRNAs, however, was significantly altered in our study of early-stage disease. To explore the physiologic relevance of miRNAs that were downregulated, we found that ectopic expression of miR23b, -145 and -221 led to decreased growth in LNCaP cells, with optimal growth inhibition approaching 100% of the frequency of transfected cells. This preliminary finding suggests that lowered expression of select miRNAs likely impacts the growth and/or survival of the prostate cancer cells. It is of interest to note that combined treatment with all three miRNAs did not generate a synergistic inhibitory effect. The possibility exists that loss of function from these regulatory molecules impacts a common, or overlapping regulatory pathways that may be pivotal for prostate cancer cell growth. The absence of an additive effect may also be attributable to the presence of a predominant, mRNA target for which the cancer cell is oncogenically addicted. 48 In the limited analysis of 16 prostatectomy samples by Ozen et al., 37 no single miRNA was useful as a predictor of recurrence, although a tendency was observed for cases with early PSA recurrence to have more global miRNA downregulation. Our preliminary findings indicate that clinically distinct subsets of prostate cancers may be distinguished according to their aggregate miRNA expression profile. The clustering of 75% of early relapse patients according to the expression pattern of 16 miRNAs represents an attractive venue for identifying patients with localized disease and a high likelihood of relapse. Of particular interest is the trend of upregulated expression of miR-135b and miR-194 that was confirmed by qRT-PCR. Bandres et al. 30 showed that miR-135b was one of the most consistently upregulated miRNAs in colorectal cancer patients, and putatively targets the mismatch repair gene MSH2. miR-194 activity has been shown to be pivotal in regulating the differentiation process of the intestinal epithelium. 49 An increased miR-194 correlated with the downregulation of its putative targets, de novo methyltransferase DNMT3a and methylbinding protein MeCP2, with hypomethylation outcomes that may contribute to genomic destabilization. 50 Phenotypic heterogeneity within each clinical subset and the limited number of patients analyzed are possible explanations for the lack of between-group statistical significance in our current study. Clearly, additional analysis with a more robust sampling population, together with molecular validation, is needed to establish the unique features of miRNA expression in early relapse prostate cancers.
